{
  "docId": "019de073-9947-75c9-ab6d-01a31b39af7e",
  "docSlug": "f6e6ee19ba9d775ca06fb17f83eb8b7f",
  "documentTitle": "Third Harmonic Bio | IPO Presentation Deck | 24 slides",
  "authorId": "third-harmonic-bio",
  "authorName": "Third Harmonic Bio",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7761332,
  "pageNumber": 6,
  "pageCount": 24,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The data highlights the mechanism of action of KIT inhibition (inactivation and depletion) supported by Phase 1b interim results.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-9947-75c9-ab6d-01a31b39af7e/6",
  "deckHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e",
  "deckJsonHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e.json",
  "deckAnchorHref": "/decks/019de073-9947-75c9-ab6d-01a31b39af7e#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.85,
        "w": 0.48,
        "x": 0.468,
        "y": 0.192
      },
      "kind": "chart",
      "text": "Barzovolimab Phase 1b Chronic Spontaneous Urticaria Interim Data",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f17b6eec-9b4b-4b40-bd22-88463bbad16d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.4,
        "x": 0.03,
        "y": 0.28
      },
      "kind": "paragraph",
      "text": "KIT (CD117) Master regulator of mast cell proliferation, migration, activation and survival. Inhibition of KIT drives both mast cell inactivation and depletion",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "277680dd-6ce6-4b89-90d5-c3709aa1d1fa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.65,
        "y": 0.84
      },
      "kind": "source-note",
      "text": "Maurer et al., EAACI, July 2022",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3447efab-3de3-4726-924c-2e1707fd6410",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.03,
        "y": 0.12
      },
      "kind": "title",
      "text": "Demonstrated clinical efficacy in chronic spontaneous urticaria",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4217f726-cfc6-418d-8fda-015c156ac50b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "Targeting KIT Has Been Shown To Broadly Inhibit Mast Cell Activity",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0b943ebd-62b1-4e4a-bc0f-9f430ca64832",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "a1cc8620-2154-4f28-a0cf-742c2b8af719",
      "evidence": "chart/line: Barzovolimab Phase 1b Chronic Spontaneous Urticaria Interim Data",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 6,
      "from": 5,
      "beatId": "d1a3d44c-6014-43c9-929f-a12d0af45eec",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Problem",
      "beatSlug": "sequoia-pitch-problem",
      "evidence": "The deck presents the problem statement on pages 5 and 6, highlighting the role of mast cells in allergy and inflammation.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 21,
      "from": 5,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "1637e937-fd9b-4682-939c-d684884ac925",
      "evidence": "The deck presents the limitations of current treatments and the potential benefits of THB001.",
      "position": 0,
      "objective": "What is the cost of not treating mast cell-mediated diseases effectively?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}